Email Alert RSS
Volume 13 Issue 5
Sep.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805
Citation: ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805
shu

Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors

  • 1.

    Department of Dermatology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National Natural Science Foundation of China 82173449

The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2019XK320024

More Information
  • Corresponding author:

    LIU Jie, E-mail: liujie04672@pumch.cn

  • Received Date: December 27, 2021
  • Accepted Date: February 23, 2022
  • Available Online: August 14, 2022
  • Issue Publish Date: September 29, 2022
    Graphical Abstract
    • Abstract
  • Death receptor pathway and perforin/granzyme pathway are the main mechanisms for immune system to kill tumor cells. SerpinB9 is the only known human protein that is able to inhibit the proteolytic activity of granzyme B (GrB). Expression of SerpinB9 has been observed in various human tumors, such as lung cancer and prostate cancer, and SerpinB9 can protect tumor cells from cytotoxic lymphocytes-mediated killing through the perforin/GrB pathway. In skin tumors, SerpinB9 expression has been detected in cells of malignant melanoma, cutaneous squamous cell carcinoma, cutaneous lymphomas, in which SerpinB9 contributes to tumor progression by mediating immune escape, resistance to immunotherapy and interference of the tumor microenvironment. In addition, researches have shown that inhibitor of SerpinB9 could retard the growth of melanoma, indicating the potential anti-tumor therapeutic application of SerpinB9 inhibition. The research status of SerpinB9 in skin tumors is reviewed in this paper.
    • FullText(HTML)
    • References (35)
  • [1]
    Irving JA, Pike RN, Lesk AM, et al. Phylogeny of the Serpin Superfamily: Implications of Patterns of Amino Acid Conservation for Structure and Function[J]. Genome Res, 2000, 10: 1845-1864. DOI: 10.1101/gr.147800
    [2]
    Kaiserman D, Bird PI. Control of Granzymes by Serpins[J]. Cell Death Differ, 2010, 17: 586-595. DOI: 10.1038/cdd.2009.169
    [3]
    Silverman GA, Whisstock JC, Askew DJ, et al. Human Clade B Serpins (Ov-serpins) Belong to a Cohort of Evolutionarily Dispersed Intracellular Proteinase Inhibitor Clades That Protect Cells From Promiscuous Proteolysis[J]. Cell Mol Life Sci, 2004, 61: 301-325. DOI: 10.1007/s00018-003-3240-3
    [4]
    Wang WJ, Wang J, Ouyang C, et al. Overview of serpin B9 and its roles in cancer (Review)[J]. Oncol Rep, 2021, 46: 190. DOI: 10.3892/or.2021.8141
    [5]
    Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the Granzyme B/Perforin Pathway Through Overexpression of the Serine Protease Inhibitor PI-9/SPI-6 Constitutes a Mechanism for Immune Escape by Tumors[J]. Proc Natl Acad Sci U S A, 2001, 98: 11515-11520. DOI: 10.1073/pnas.201398198
    [6]
    Sun JR, Bird CH, Sutton V, et al. A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic Lymphocytes[J]. J Biol Chem, 1996, 271: 27802-27809. DOI: 10.1074/jbc.271.44.27802
    [7]
    Zhang ML, Park SM, Wang Y, et al. Serine Protease Inhibitor 6 Protects Cytotoxic T Cells From Self-inflicted Injury by Ensuring the Integrity of Cytotoxic Granules[J]. Immunity, 2006, 24: 451-461. DOI: 10.1016/j.immuni.2006.02.002
    [8]
    Ansari AW, Temblay JN, Alyahya SH, et al. Serine Protease Inhibitor 6 Protects iNKT Cells From Self-inflicted Damage[J]. J Immunol, 2010, 185: 877-883. DOI: 10.4049/jimmunol.1000651
    [9]
    Bird CH, Sutton VR, Sun J, et al. Selective Regulation of Apoptosis: the Cytotoxic Lymphocyte Serpin Proteinase Inhibitor 9 Protects Against Granzyme B-mediated Apoptosis Without Perturbing the Fas Cell Death Pathway[J]. Mol Cell Biol, 1998, 18: 6387-6398. DOI: 10.1128/MCB.18.11.6387
    [10]
    Kummer JA, Micheau O, Schneider P, et al. Ectopic Expression of the Serine Protease Inhibitor PI9 Modulates Death Receptor-mediated Apoptosis[J]. Cell Death Differ, 2007, 14: 1486-1496. DOI: 10.1038/sj.cdd.4402152
    [11]
    Cunningham TD, Jiang XG, Shapiro DJ. Expression of High Levels of Human Proteinase Inhibitor 9 Blocks Both Perforin/Granzyme and Fas/Fas Ligand-mediated Cytotoxi-city[J]. Cell Immunol, 2007, 245: 32-41. DOI: 10.1016/j.cellimm.2007.03.004
    [12]
    Bladergroen BA, Strik MC, Bovenschen N, et al. The Granzyme B Inhibitor, Protease Inhibitor 9, Is Mainly Expressed by Dendritic Cells and at Immune-privileged Sites[J]. J Immunol, 2001, 166: 3218-3225. DOI: 10.4049/jimmunol.166.5.3218
    [13]
    Azzi J, Skartsis N, Mounayar M, et al. Serine Protease Inhibitor 6 Plays a Critical Role in Protecting Murine Granzyme B-producing Regulatory T Cells[J]. J Immunol, 2013, 191: 2319-2327. DOI: 10.4049/jimmunol.1300851
    [14]
    Bladergroen BA, Strik MCM, Wolbink AM, et al. The Granzyme B Inhibitor Proteinase Inhibitor 9 (PI9) Is Expressed by Human Mast Cells[J]. Eur J Immunol, 2005, 35: 1175-1183. DOI: 10.1002/eji.200425949
    [15]
    Buzza MS, Hirst CE, Bird CH, et al. The Granzyme B Inhibitor, PI-9, Is Present in Endothelial and Mesothelial Cells, Suggesting That It Protects Bystander Cells During Immune Responses[J]. Cell Immunol, 2001, 210: 21-29. DOI: 10.1006/cimm.2001.1806
    [16]
    Rizzitelli A, Meuter S, Vega Ramos J, et al. Serpinb9 (Spi6)-deficient Mice Are Impaired in Dendritic Cell-mediated Antigen Cross-presentation[J]. Immunol Cell Biol, 2012, 90: 841-851. DOI: 10.1038/icb.2012.29
    [17]
    Garrido F. MHC/HLA Class I Loss in Cancer Cells[J]. Adv Exp Med Biol, 2019, 1151: 15-78.
    [18]
    Rousalova I, Krepela E, Prochazka J, et al. Expression of Proteinase Inhibitor-9/serpinB9 in Non-small Cell Lung Carcinoma Cells and Tissues[J]. Int J Oncol, 2010, 36: 275-283.
    [19]
    Soriano C, Mukaro V, Hodge G, et al. Increased Proteinase Inhibitor-9 (PI-9) and Reduced Granzyme B in Lung Cancer: Mechanism for Immune Evasion?[J]. Lung Cancer, 2012, 77: 38-45. DOI: 10.1016/j.lungcan.2012.01.017
    [20]
    Zhou B, Chen EL, Chen JH, et al. Overexpression of Proteinase Inhibitor 9 Is Associated With Poor Prognosis in Human Hepatocellular Carcinoma and With Proliferation and Apoptosis in HepG2 Cells in vitro[J]. Int J Clin Exp Pathol, 2019, 12: 3719-3727.
    [21]
    Vycital O, Pitule P, Hosek P, et al. Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer[J]. Anticancer Res, 2019, 39: 6063-6066. DOI: 10.21873/anticanres.13813
    [22]
    Ray M, Hostetter DR, Loeb CRK, et al. Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis[J]. Prostate, 2012, 72: 846-855. DOI: 10.1002/pros.21486
    [23]
    Fritsch K, Finke J, Grüllich C. Suppression of Granzyme B Activity and Caspase-3 Activation in Leukaemia Cells Constitutively Expressing the Protease Inhibitor 9[J]. Ann Hematol, 2013, 92: 1603-1609. DOI: 10.1007/s00277-013-1846-6
    [24]
    Chen Y, Quan LN, Jia CM, et al. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma[J]. J Proteome Res, 2021, 20: 2673-2686. DOI: 10.1021/acs.jproteome.1c00007
    [25]
    van Houdt IS, Oudejans JJ, van den Eertwegh AJM, et al. Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients With Stage Ⅲ and Ⅳ Melanoma[J]. Clin Cancer Res, 2005, 11: 6400-6407. DOI: 10.1158/1078-0432.CCR-05-0306
    [26]
    Van Allen EM, Miao DN, Schilling B, et al. Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma[J]. Science, 2015, 350: 207-211. DOI: 10.1126/science.aad0095
    [27]
    Jiang P, Gu SQ, Pan D, et al. Signatures of T cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response[J]. Nat Med, 2018, 24: 1550-1558. DOI: 10.1038/s41591-018-0136-1
    [28]
    Jiang XJ, Wang J, Deng XY, et al. Role of the Tumor Microenvironment in PD-L1/PD-1-mediated Tumor Immune Escape[J]. Mol Cancer, 2019, 18: 10. DOI: 10.1186/s12943-018-0928-4
    [29]
    Jiang LW, Wang YJ, Zhao J, et al. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy[J]. Cell, 2020, 183: 1219-1233. e18. DOI: 10.1016/j.cell.2020.10.045
    [30]
    Liu Y, Cao XT. Immunosuppressive Cells in Tumor Immune Escape and Metastasis[J]. J Mol Med (Berl), 2016, 94: 509-522. DOI: 10.1007/s00109-015-1376-x
    [31]
    Luo H, Ma C. Identification of Prognostic Genes in Uveal Melanoma Microenvironment[J]. PLoS One, 2020, 15: e0242263. DOI: 10.1371/journal.pone.0242263
    [32]
    Peters FS, Peeters AMA, van den Bosch TPP, et al. Disrupted Regulation of serpinB9 in Circulating T Cells Is Associated With an Increased Risk for Post-transplant Skin Cancer[J]. Clin Exp Immunol, 2019, 197: 341-351. DOI: 10.1111/cei.13309
    [33]
    Bladergroen BA, Meijer CJLM, ten Berge RL, et al. Expression of the Granzyme B Inhibitor, Protease Inhibitor 9, by Tumor Cells in Patients With non-Hodgkin and Hodgkin Lymphoma: a Novel Protective Mechanism for Tumor Cells to Circumvent the Immune System?[J]. Blood, 2002, 99: 232-237. DOI: 10.1182/blood.V99.1.232
    [34]
    ten Berge RL, Meijer CJLM, Dukers DF, et al. Expression Levels of Apoptosis-related Proteins Predict Clinical Outcome in Anaplastic Large Cell Lymphoma[J]. Blood, 2002, 99: 4540-4546. DOI: 10.1182/blood.V99.12.4540
    [35]
    Bossard C, Belhadj K, Reyes F, et al. Expression of the Granzyme B Inhibitor PI9 Predicts Outcome in Nasal NK/T-cell Lymphoma: Results of a Western Series of 48 Patients Treated With First-line Polychemotherapy Within the Grouped'Etude des Lymphomes de l'Adulte (GELA) Trials[J]. Blood, 2007, 109: 2183-2189. DOI: 10.1182/blood-2006-07-033142
    • Related Articles

  • Related Articles

    [1]ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
    [2]WU Yaru, ZHAO Yuebin, LIU Shiwei. A Case of Diabetes Mellitus Type 2 Complicated with Malignant Melanoma Misdiagnosed as Diabetic Foot Ulcer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 1009-1015. DOI: 10.12290/xhyxzz.2021-0053
    [3]LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. DOI: 10.12290/xhyxzz.20190100
    [4]LIU Yanting, ZHANG Lu, CHEN Miao, ZHANG Yan, WEI Chong, PAN Boju, ZHAO Jiawei. A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 423-426. DOI: 10.12290/xhyxzz.20200063
    [5]LIU Jie, LUO Yi-xin, LIU Zhao-rui, LIU Yue-hua, ZHANG Wei, LU Zhao-hui. WHO-EORTC Classification of Primary Cutaneous Lymphomas:Updates and Interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 698-702. DOI: 10.3969/j.issn.1674-9081.2020.06.011
    [6]Jian-hua DENG, Han-zhong LI. Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 91-95. DOI: 10.3969/j.issn.1674-9081.20170164
    [7]Shi-qi WANG, Cheng CHI, Jie LIU. Advance in the Topical Medication and Physical Therapy for Cutaneous T Cell Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 157-161. DOI: 10.3969/j.issn.1674-9081.2019.02.014
    [8]Hai-jing WU, Si-qi FU, Qian-wen LI, Hui-ming ZHANG, Qian-jin LU, Zhong GUO. Biomarkers of Melanoma: from Genetics to Epigenetics[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 60-68. DOI: 10.3969/j.issn.1674-9081.2018.01.012
    [9]Ning-yi CUI, Yong WANG, Ke Lü, Shuang-mei ZOU, Rui ZHANG, Jun-ying LIU, Yu-zhi HAO, Yu-xin JIANG. Lymphoma and Stromal Tumor of the Small Intestine: Ultrasound Findings and Differential Diagnosis[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(5): 342-346. DOI: 10.3969/j.issn.1674-9081.2016.05.004
    [10]Li GE, Rui-e FENG, Xin-lun TIAN, Ju-hong SHI, Tao LIU, Zuo-jun XU, Wen-bing XU, Wei SONG, Hong-rui LIU, Yuan-jue ZHU. Clinical and Pathological Features of Pulmonary Intravascular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 30-35. DOI: 10.3969/j.issn.1674-9081.2012.01.008

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (430) PDF downloads (46) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close